Daiichi Sankyo/AstraZeneca’s Enhertu Shows Positive Results in Phase III DESTINY-Breast06 Clinical Trial
- “Miracle Weight-Loss Drug” Sweeps Across America
- The United States Avian Influenza Outbreak Worse Than Expected?
- Global First: Bovine Avian Influenza Transmission to Humans Detected
- Potassium-Enriched Salt Substitutes: Reducing Blood Pressure Risk?
- Tritium Detection in Fukushima’s Seawater: Below Safety Standards
- What Reason Let AstraZeneca Withdraws COVID Vaccine From The Market?
Daiichi Sankyo/AstraZeneca’s Enhertu Shows Positive Results in Phase III DESTINY-Breast06 Clinical Trial
- AstraZeneca Admits for the First Time that its COVID Vaccine Has Blood Clot Side Effects
- Was COVID virus leaked from the Chinese WIV lab?
- HIV Cure Research: New Study Links Viral DNA Levels to Spontaneous Control
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
Daiichi Sankyo/AstraZeneca’s Enhertu Shows Positive Results in Phase III DESTINY-Breast06 Clinical Trial
On April 29, Daiichi Sankyo announced that the Phase III clinical trial of Enhertu, DESTINY-Breast06, has achieved positive top-line results.
The study results showed that in the primary trial population, consisting of HR-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) metastatic breast cancer patients receiving one or more endocrine therapies, Enhertu demonstrated a statistically significant and clinically meaningful improvement in PFS compared to standard of care chemotherapy. Additionally, in the overall population, including HER2-low and HER2-negative (IHC 0; IHC >0 <1+) metastatic breast cancer patients, an improvement in PFS was also observed.
Although overall survival (OS) data are not yet mature, early trends of OS improvement compared to standard of care chemotherapy were observed in patients with HER2-low breast cancer and in the overall population. The trial will continue to evaluate OS and other secondary endpoints. Safety profiles were consistent with those observed in previous trials, and no new safety signals were identified. Detailed result data will be presented at an upcoming medical meeting.
DESTINY-Breast06 (DB06) is a Phase III clinical trial for HR-positive HER2-low breast cancer, enrolling patients who have progressed following endocrine therapy and have not received prior chemotherapy (post ET, chemo-naive) for metastatic breast cancer.
The previously positive DB04 trial targeted patients who had received prior endocrine therapy and one to two lines of chemotherapy regardless of HR status. The positive results from DB06 signify a shift in the treatment paradigm for HER2-low breast cancer.
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
